Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-24-035289
Filing Date
2024-11-14
Accepted
2024-11-14 16:01:45
Documents
72
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q nrxp20240930_10q.htm   iXBRL 10-Q 1736433
2 EXHIBIT 31.1 ex_717342.htm EX-31.1 11932
3 EXHIBIT 31.2 ex_717343.htm EX-31.2 11758
4 EXHIBIT 32.1 ex_717344.htm EX-32.1 5301
5 EXHIBIT 32.2 ex_717345.htm EX-32.2 5357
11 nrxp-20240331x10q001.jpg GRAPHIC 72207
12 nrxp-20240331x10q002.jpg GRAPHIC 48140
  Complete submission text file 0001437749-24-035289.txt   8736183

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20240930.xsd EX-101.SCH 69204
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nrxp-20240930_cal.xml EX-101.CAL 35413
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20240930_def.xml EX-101.DEF 521434
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20240930_lab.xml EX-101.LAB 416134
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20240930_pre.xml EX-101.PRE 544946
75 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20240930_10q_htm.xml XML 1355565
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38302 | Film No.: 241461569
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)